NET

MSc. in any branch of biological sciences from any reputed university, institute. Should be qualified any national level examination

Candidate with hands-on experience in materials science and device fabrication will be preferred. Candidates having prior experience in working with the development of lateral flow assays/scaffolds using biomaterials is desirable.

Sepsis related mortality in neonates in India: A multi-disciplinary, multi- institutional research program for context specific solutions. Masters degree in Life Sciences, Biotechnology OR Graduate or Postgraduate degree in Professional Course from a recognized university with two years of post-qualification experience in the relevant field

First-class Masters degree, including the integrated Masters degree in Biochemistry, Biotechnology, Zoology, Life Sciences or allied areas. Additionally, candidates should have qualified NET, GATE.

M.Sc, M.Tech, M.Pharm IPR from a recognized University. The incumbent should have sound knowledge of Patent Act, 1970 and should possess five years post qualification experience in dealing with issues like filling of Patent, Design, Copy Right & Trade Marks. OR The incumbent having 05 years working experience with Patent Office issues in a responsible position dealing with examination and granting of patents will be preferred.

M.Sc. in Life Science, Botany, Forestry with minimum of 2 years experience in Medicinal, Aromatic and Plants with high quality publication

M.Sc, MS, M.Tech in Biology or related discipline. The candidate should have experience with rodent behavioural experiments, stereotaxic surgery, rodent brain dissection, immunohistochemistry, western blot and other molecular biological techniques.

M.Sc./ M.Tech./ M.Pharm./ B.Tech. or equivalent in Biotechnology and allied areas; Research project entitled Targeting Autophagy and Microtubule Dynamics for Next- Generation Cancer and Neurovegetative Disease Treatment funded by Gujarat State Biotechnology Mission, Govt. of Gujarat.

Development of strategies to make Host Defence Peptides pragmatically applicable for clinical use as adjunct host directed therapy against drug sensitive and resistant tuberculosis.